{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '124', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.1.3.1', 'Confidentiality of Data', 'By signing this protocol, the investigator affirms to the Sponsor that information furnished to', 'the investigator by the Sponsor will be maintained in confidence, and such information will', 'be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and', 'employees, only under an appropriate understanding of confidentiality with such board or', 'committee, affiliated institution and employees. Data generated by this study will be', 'considered confidential by the investigator, except to the extent that it is included in a', 'publication as provided in the Publications section of this protocol.', '10.1.3.2', 'Confidentiality of Participant Records', 'By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative),', 'IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to', 'verify worksheet/CRF data. By signing the consent form, the participant agrees to this', 'process. If study documents will be photocopied during the process of verifying', 'worksheet/CRF information, the participant will be identified by unique code only; full', 'names/initials will be masked prior to transmission to the Sponsor.', 'By signing this protocol, the investigator agrees to treat all participant data used and', 'disclosed in connection with this study in accordance with all applicable privacy laws, rules', 'and regulations.', '10.1.3.3', 'Confidentiality of IRB/IEC Information', 'The Sponsor is required to record the name and address of each IRB/IEC that reviews and', 'approves this study. The Sponsor is also required to document that each IRB/IEC meets', 'regulatory and ICH GCP requirements by requesting and maintaining records of the names', 'and qualifications of the IRB/IEC members and to make these records available for', 'regulatory agency review upon request by those agencies.', '10.1.4', 'Committees Structure', '10.1.4.1', 'Steering Committee', 'This study will be conducted in consultation with a Steering Committee. The Steering', 'Committee is composed of the following:', 'Sponsor personnel', 'Eisai personnel', 'Investigators participating in the study', 'Consulting therapeutic area and clinical study experts', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '125', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'The Steering Committee will provide guidance on the operational aspects of the study and', 'provide input with respect to study design, interpretation of results, and subsequent', 'peer-reviewed scientific publications.', 'Specific details regarding responsibilities and governance of the Steering Committee will be', 'described in a separate charter.', '10.1.4.2', 'Executive Oversight Committee', 'The EOC is composed of members of Sponsor Senior Management. The EOC will receive', 'and decide upon any recommendations made by the DMC or Steering Committee regarding', 'the study.', '10.1.4.3', 'External Data Monitoring Committee', 'To supplement the routine study monitoring outlined in this protocol, an external DMC will', 'monitor the interim data from this study. The voting members of the committee are external', 'to the Sponsor. The members of the DMC must not be involved with the study in any other', 'way (eg, they cannot be study investigators) and must have no competing interests that could', 'affect their roles with respect to the study.', 'The DMC will make recommendations to the EOC regarding steps to ensure both participant', 'safety and the continued ethical integrity of the study. Also, the DMC will review interim', 'study results, consider the overall risk and benefit to study participants (Section 9.7, Interim', 'Analysis) and recommend to the EOC whether the study should continue in accordance with', 'the protocol.', 'Specific details regarding composition, responsibilities, and governance, including the roles', 'and responsibilities of the various members and the Sponsor protocol team OR external', 'collaborating organization protocol team; meeting facilitation; the study governance', 'structure; and requirements for and proper documentation of DMC reports, minutes, and', 'recommendations will be described in the DMC charter that is reviewed and approved by all', 'the DMC members.', '10.1.5', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. The Sponsor', 'will comply with the requirements for publication of study results. In accordance with', 'standard editorial and ethical practice, the Sponsor will generally support publication of', 'multicenter studies only in their entirety and not as individual site data. In this case, a', 'coordinating investigator will be designated by mutual agreement.', 'If publication activity is not directed by the Sponsor, the investigator agrees to submit all', 'manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect', 'proprietary information and to provide comments.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}